Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month  12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO

ConclusionThis real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month  6 in the anti-IL-17A cohort compared to the other biologics cohort. Of the individual biologics studied, ixekizumab showed the highest numerical improvements in nail psoriasis at month 12.Trial registrationEUPAS24207.
Source: Dermatology and Therapy - Category: Dermatology Source Type: research